UK increasingly less favored for clinical trial research

A stark warning on UK access to innovation has been issued by the Association of the British Pharmaceutical Industry (ABPI).

Research undertaken by the trade group outlines a falling number of clinical trials initiated in the UK over time, undermining patient care and negatively impacting the country’s national healthcare provider, as well as economic growth broadly.

The report shows that the number of industry clinical trials initiated in the UK per year fell by 41% between 2017 and 2021, with late-stage studies falling by a higher margin.